Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
Bonita Gu, Kavya Venkatesh, Astrid‐Jane Williams, Watson Ng, Crispin Corte, Ali Gholamrezaei, Simon Ghaly, Xuan Wei, Sudarshan Paramsothy, Susan J. Connor
Abstract
BACKGROUND: Tumor necrosis factor-alpha inhibitors, including infliximab and adalimumab, are effective medical treatments for perianal fistulising Crohn's disease (CD), but not all patients achieve fistula healing. AIM: To determine the correlation between perianal fistula healing and closure with infliximab and adalimumab trough levels. METHODS: test. RESULTS: = 0.083]. CONCLUSION: Higher maintenance infliximab and adalimumab trough levels are associated with perianal fistula healing in CD.
Topics & Concepts
AdalimumabInfliximabMedicineFistulaSurgeryCrohn's diseaseInflammatory bowel diseaseGastroenterologyInternal medicineDiseaseInflammatory Bowel DiseaseDiverticular Disease and ComplicationsMicroscopic Colitis